Pharmacy Exam Review

GERD, PUD

Updates: Nov 3rd, 2021
March 30th, 2020

GERD Background

  • Occurred when stomach content leak backward into the esophagus. Symptoms include heartburn, regurgitation, and acidic taste, recurrent cough, hoarseness, chest pain. If esophageal erosion is present, use PPI as the first line.
  • Drug treatment steps up from anti-acids to H2RAs, finally to PPIs.

 

Non-drug treatment

  • Avoiding food that may reduce lower esophageal sphincter (LES) pressure: spicy food, coffee, alcohol, chocolate.
  • Avoid drugs that reduce LES pressure: nicotine (encourage smoking cessation).
  • Do not eat before sleep.
  • Elevate the head of bed 6-8" with a wedge.

 

Anti-acid

  • Drugs: TUMs, Mag-Al-Simethicone (anti-gas), Gaviscon (also contains alginic acid)
  • SE: constipation (Al), diarrhea (Mg) (used together to counterbalance), Al and Mg are metals that can accumulate in renal (avoid in kidney disease). Alka-Seltzer contains >1g Na (high sodium content should be avoided in high BP).
  • DDI: Separate with quinolones and tetracyclines due to chelation (2-hrs before, 4-hrs after), itra/ketoconazole (needs acid environment to work), Ca carbonate and iron (reduced absorption from increased pH).

 

H2RA blockers (Histamine-2 receptor antagonists)

  • Drugs: Famotidine (Pepcid), Ranitidine (Zantac), Cimetidine (Tagamet), Nizatidine (Axid)
  • MOA: Binds reversibly to histamine2 receptor on parietal cells in the stomach.
  • Second-line for an NSAID-induced ulcer.
  • May increase risk of GI infection/pneumonia (stomach’s acidic environment is an important body defense mechanism, less acid may lead to more bacteria surviving) worsen renal function, CNS (HA, confusion, dizziness due to blocking of histamine receptors). Cimetidine has lots of side effects: CNS effect (common to lipophilic agents), gynecomastia (due to androgen blocking, also is more common with lipophilic agents), blood dyscrasias, increase LFT (makes sense to have CYP interactions), arthralgia.
  • DDI: Cimetidine is a potent 3A4 inhibitor, and thus has more interactions compared to other H2RAs.

 

Proton pump inhibitors (PPIs)

  • Drugs: omeprazole (Prilosec), pantoprazole (Protonix), rabeprazole (Aciphex), esomeprazole (Nexium), lansoprazole (Prevacid), Zegerid (omeprazole/Na Bicarb), Dexilant (dexlansoprazole)
  • MOA: Irreversibly binds parietal cells.
  • First-line therapy in NSAID-induced ulcer.
  • SE: increase risk of C. diff & pneumonia (less acid may lead to more bacteria surviving), osteoporosis/fracture (ensure sufficient Ca supplement), ↑ INR (risk of bleeding).
  • Recommend Ca citrate (instead of carbonate) as a calcium supplement for better absorption.
  • Effervescent and ODT contain phenylalanine, do not use in PKU.
  • Available as OTC now: Prilosec, Nexium, Prevacid, Zegerid.
  • DDI: Omeprazole/esomeprazole are 2C19 inhibitors that prevent the conversion of clopidogrel to its active form, less effective antiplatelet treatment; Caution use in drugs prefer acidic environment: azoles (itra/ketoconazole), Ca carbonate, iron (absorption would be better).

 

Metoclopramide (Reglan)

  • MOA: Dopamine receptor antagonist (both peripheral and central), 5-HT4 receptor agonist (migraine treatment “triptans” are 5HT-1 agonists with vasoconstrictive effects) and a direct stimulant of gastric smooth muscle with prokinetic and antiemetic effects, thus facilitate gastric emptying (may also reduce LES sphincter pressure, food content is less likely to move back to the esophagus).
  • It is the only FDA-approved medication for gastroparesis.
  • SE: CNS (dizziness, somnolence, fatigue, depression), movement disorders (EPS & Parkinson-like symptoms which are common to antipsychotics from Schizophrenia chapter).
  • CI: GI obstruction/movement disorders (more stimulation would be futile), history of seizure.
  • 10mg QID 30 mins before meals and HS; Decrease dose 50% if CrCl < 40.

 

Peptic ulcer disease (PUD)

Background

  • Mucosal erosion within the GI tract, compared to GERD, this condition seems more austere.
  • Causes: H. pylori (responsible for most peptic ulcers), chronic use of NSAIDs or ASA, or from hypersecretory states (e.g: Zollinger-Ellison syndrome: increased gastric acid).
  • The primary symptom is epigastric pain.

H. pylori Treatment

  • Triple therapy: PPI + 2 antibiotics (clarithromycin 500mg, amoxicillin1000mg) BID x 14 days
    • If PCN or macrolide allergy: replace with metronidazole
    • Use backup method during antibiotic therapy
    • Prevpac: lansoprazole (Prevacid), amoxicillin, clarithromycin.
  • Quadruple therapy: PPI BID+ (bismuth + metronidazole + tetracycline) QID x 10-14 days.
    • Who’d want to use quadruple drugs instead of triple drugs? Chose if a patient used a macrolide or metronidazole in the past or recent failure with triple therapy.
    • Pylera (bismuth, metronidazole, TCN).
    • Notice that PPI dosing frequency is at most BID. Therefore it does not follow the schedule of the other 3 drugs.
    • Avoid alcohol (CI with metronidazole), pregnancy &children (TCN), salicylate allergy (bismuth subsalicylate).
  • Sequential therapy: PPI +Amoxil x 5 days followed by PPI + clarithromycin + tinidazole x 5 days

 

NSAIDs-induced ulcer

  • High dose induces GI ulcers (risk factor: >65 y/o, use of steroid, anticoagulant, previous ulcer). Caution use of NSAID in CV (vasoconstriction of renal tubules leads to edema and increase BP, ↑CV risk) or renal disease (decreased renal blood flow).
  • 1st line: PPI.
  • 2nd line: H2RA or misoprostol.

Misoprostol (Cytotec, + diclofenac = Arthrotec)

  • MOA: prostaglandin analog, replaces protective prostaglandins that have been removed by NSAIDs. Not first line in NSAID-induced ulcer.
  • SE: diarrhea, abdominal pain (if its primary action site is in the GI, then it’s going to cause GI side effects) This is also used in abortive therapy, which explains its abdominal side effects.
  • Start 100mcg after diner, not the first line in NSAID-induced ulcer.

Sucralfate (Carafate)

  • MOA: a complex of aluminum hydroxide and sucrose. It dissociates in the acid environment and binds to the ulcer base. This creates a protective barrier to pepsin and bile and inhibits the diffusion of gastric acid.
  • SE: constipation (aluminum complex), avoid in renal disease (heavy metal accumulation).
  • 1 g tab QID before meals and HS.
  • Not the first line in NSAID-induced ulcer.

 

 

Quiz

 

  1. A patient using NSAIDs chronically and develops a bleeding ulcer. Which of the following medications would be MOST appropriate to treat his condition?
    1. Magnesium hydroxide
    2. Bismuth subsalicylate
    3. Calcium carbonate
    4. Metoclopramide
    5. Misoprostol

 

  1. A patient takes warfarin for chronic atrial fibrillation develops GERD. Which of the following medications would most likely interact with warfarin and increase patient’ s risk for bleeding?
    1. Cimetidine
    2. Magnesium hydroxide
    3. Misoprostol
    4. Omeprazole
    5. Misoprostol

 

  1. Which of the following reasons could explain why the plasma levels of ketoconazole are decreased in patients taking pantoprazole?
    1. Pantoprazole induces the CYP450 enzymes that metabolize ketoconazole.
    2. Ketoconazole requires an acidic environment for its oral absorption.
    3. Pantoprazole binds acidic drugs in the GI tract.
    4. Pantoprazole has prokinetic effects, which decrease GI transit time.

 

  1. Which of the following medications needs to be dose-adjusted in patients with renal impairment? (Select ALL that apply.)
    1. Infliximab
    2. Budesonide
    3. Esomeprazole
    4. Metoclopramide
    5. Ranitidine

 

  1. Which of the following is a contraindication for the use of metoclopramide?
    1. Hyperkalemia
    2. Myasthenia gravis
    3. Porphyria
    4. Seizure disorder
    5. Sulfa allergy

 

 

  1. E. The first-line therapy for an NSAID-induced ulcer is a PPI. However, PPIs is not among the answer choices. Second-line therapies are either misoprostol or an H2RA. Misoprostol is a prostaglandin E1 analog that acts to replace protective prostaglandins that have been stripped away by NSAIDs.
  2. A. Cimetidine is a strong CYP3A4 inhibitor, a moderate inhibitor of CYP1A2, and a weak inhibitor of CYP2C9. (R)-warfarin is a substrate of CYP3A4 and CYP1A2, (S)-warfarin is a substrate of CYP2C9. Therefore, cimetidine may inhibit the metabolism of both the (S)- and (R)-enantiomers of warfarin, which could lead to an increased risk of bleeding. All other choices do not inhibit the CYP450 system.
  3. B. The absorption of ketoconazole is pH-dependent, of which requires an acidic environment to be adequately absorbed; the bioavailability of this drug decreases as gastric pH increases. By increasing gastric pH, pantoprazole may reduce the absorption of ketoconazole, which would lead to decreased plasma concentrations. Pantoprazole is not an inducer of the CYP450; metoclopramide has prokinetic effects in the GI tract.
  4. DE. Both metoclopramide and ranitidine are primarily excreted in the urine as unchanged drug. Therefore, the doses of these drugs need to be adjusted in patients with renal impairment. This suggests hydrophilic property of the drug. All H2RAs needs to be adjusted in renal impairment. None of the PPIs needs to be dose adjusted in renal impairment. Also, neither Infliximab nor budesonide needs to be dose-adjusted.
  5. D. Seizure disorder is a contraindication for the use of metoclopramide.  Although B. Myasthenia gravis (weak muscle tone) seem like a correct answer, but metoclopramide is an antipsychotic, and it is contraindicated in movement disorder, and seizure is listed as one of the contraindications.



Was this page helpful?




Back to top »